Prescribing practices of primary-care veterinary practitioners in dogs diagnosed with bacterial pyoderma by Summers, J F et al.
Summers et al. BMC Veterinary Research 2014, 10:240
http://www.biomedcentral.com/1746-6148/10/240RESEARCH ARTICLE Open AccessPrescribing practices of primary-care veterinary
practitioners in dogs diagnosed with bacterial
pyoderma
Jennifer F Summers1*, Anke Hendricks2 and David C Brodbelt1Abstract
Background: Concern has been raised regarding the potential contributions of veterinary antimicrobial use to
increasing levels of resistance in bacteria critically important to human health. Canine pyoderma is a frequent, often
recurrent diagnosis in pet dogs, usually attributable to secondary bacterial infection of the skin. Lesions can range in
severity based on the location, total area and depth of tissue affected and antimicrobial therapy is recommended for
resolution. This study aimed to describe patient signalment, disease characteristics and treatment prescribed in a large
number of UK, primary-care canine pyoderma cases and to estimate pyoderma prevalence in the UK vet-visiting
canine population.
Results: Of 54,600 dogs presented to 73 participating practices in 2010, 683 (1.3%) had a pyoderma diagnosis recorded
in available electronic patient record (EPR) data. Antimicrobials were dispensed in 97% of cases and most dogs were
prescribed systemic therapy (92%). Agents most frequently prescribed were amoxicillin-clavulanate, cefalexin, clindamycin
and cefovecin. Systemic antimicrobials were prescribed for fewer than 14 days in around 40% of study cases reviewed in
detail. Prescribed daily doses were below minimum recommended daily dose (MRDD) in 26% of 43 dogs with sufficient
information for calculation of minimum dose.
Conclusions: Antimicrobial prescribing behaviour for treatment of canine pyoderma was variable but frequently
appeared inconsistent with current recommendations. Use of clinical data from primary practice EPRs can provide
valuable insight into common clinical conditions and associated prescribing.
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Canine pyoderma results from bacterial infection of the
skin and associated structures. Presentations can include a
wide range of clinical lesions from erythema, alopecia and
pruritus to macules, papules, pustules, crusts, collarettes,
scaling, deep folliculitis, furunculosis, dermal fistulae, cel-
lulitis, panniculitis and vasculitis. Clinical sub-division of
the condition into surface, superficial and deep pyoderma
is made according to the depth and extent of bacterial in-
fection present within cutaneous tissue. In the dog, the
most commonly isolated causal pathogen is the coagulase
positive staphylococcal species known as S. pseudinterme-
dius. Other staphylococcal (e.g. S. aureus, S. schleiferi) and* Correspondence: jsummers@rvc.ac.uk
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unless otherwise stated.non-staphylococcal bacteria (e.g. Escherichia coli, Pseudo-
monas or Proteus species) can also be isolated from af-
fected skin in some cases. While these species can act as
primary pyoderma pathogens, particularly in immune-
compromised patients, they are usually secondary infec-
tious agents or simply lesion contaminants [1-3]. Canine
pyoderma is usually secondary to one or more underlying
disease processes which compromise the defence mecha-
nisms protecting the skin from infection [4-7]. Recurrence
of pyoderma lesions after successful antimicrobial treat-
ment is common if primary conditions remain undiag-
nosed or are not appropriately managed.
Clinical consequences for individual affected dogs and
the scale of disease-burden at a population level are both of
concern when considering the overall impact of pyoderma
on canine welfare. The condition causes varying degrees of
pain and pruritus depending on depth and extent ofral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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common reasons for presentation of pet dogs for veterinary
care [10,11], and several reports support the clinical im-
pression that canine pyoderma appears to be a relatively
common diagnosis [12-15]. In addition, recent evidence-led
guidelines agree that antimicrobial treatment, either topical,
systemic or both, is indicated in all but the mildest cases of
pyoderma in the dog (i.e. those involving only a small num-
ber of extremely localised superficial lesions) [16-18]. Thus,
clarification of the impact of canine pyoderma on dog wel-
fare, as well as the level and appropriateness of antimicro-
bial usage for the condition in the UK is required. Large
scale, UK-specific surveys using data from the primary clin-
ical practice setting could provide an estimate of the pro-
portion vet-visiting dogs affected by pyoderma over a
specified period of time, and provide insight into the extent
and nature of associated antimicrobial prescribing by vets
managing these dogs. This information could facilitate
evidence-based assessment of the potential impact of the
condition in the UK with respect to animal welfare as well
as exploring whether veterinary antimicrobial usage is in
accordance with current guidelines [18].
This study aimed to use pre-existing electronic patient
health record (EPR) data from a large number of UK pri-
mary practices to describe the frequency of the condi-
tion and the treatment approaches adopted for canine
pyoderma as managed by first opinion veterinary practi-
tioners in the UK.
Results
Prevalence of diagnosis with pyoderma
A total of 683 dogs with at least one reported diagnosis of
pyoderma in the year 2010 were identified using available
EPRs from 73 individual practices. The total number of in-
dividual dogs with one or more clinical encounters (for any
reason) recorded by any of these VetCompass-participating
practices during the year 2010 was 54,600. Thus, 1.3% (95%
confidence interval (CI) 1.2-1.4%) of all dogs presented for
any reason to participating practices in 2010 were diag-
nosed with pyoderma at least once during that year. Based
on in-depth case review in the randomly selected subgroup
(see later), a 10% misclassification rate was estimated, sug-
gesting the true prevalence within the study period was ap-
proximately 1.1% (95% CI 1.0-1.2%).
Characteristics of dogs diagnosed with pyoderma
Of all 683 identified cases, 392 (57%) were male. Neuter-
ing status at the time of the earliest pyoderma episode in
2010 was clearly recorded in 455 (66.6%) identified cases
and 425 (93.4%) of these were neutered. Neutering status
at this time was neither recorded nor deducible from
available information in the remaining 228 cases. Median
age at diagnosis was 5.0 years and ranged from 0.1 –
16.2 years (i.e. between approximately 5 weeks and16 years 10 weeks). Weight was recorded on the date of
diagnosis in 369 study dogs (54.0%) and ranged from
1.2 – 81.5 (median 19.2) kgs. At least one weight value
was recorded within 28 days of the date of diagnosis in
478 dogs (70.0%), within six calendar months in 594
dogs (87.0%) and within one year in 629 dogs (92.1%).
Of 90 different breeds represented, those accounting for at
least 3% of all study dogs were the crossbreed (105 dogs,
15%), Labrador retriever (61, 9%), West Highland White
terrier (54, 8%), Staffordshire bull terrier (50, 7%), German
shepherd dog (38, 6%), Cocker spaniel (31, 5%), Golden
retriever (26, 4%), Yorkshire terrier (24, 4%) and Jack
Russell terrier (22, 3%).
Prescribing of systemic and topical antimicrobial
treatment
Within 24 hours of the diagnosis of pyoderma, 659 cases
(96.5%) were prescribed at least one antimicrobial product
for administration systemically and/or topically; most dogs
(91.9%) were prescribed at least one systemic antimicro-
bial, either alone (64.1%) or in combination with a topical
product (27.7%). Few dogs were prescribed a topical prod-
uct only, or no antimicrobial treatment at all (Figure 1).
Agents most frequently prescribed for systemic antimicro-
bial treatment were amoxicillin-clavulanic acid (350 dogs,
55.7% of the 628 dogs prescribed a systemic antimicro-
bial), cefalexin (276 dogs, 43.9% of 628) and clindamycin
(63 dogs, 10.0% of 628) (Figure 2). In total 220 study dogs
(32.2%) were prescribed at least one topical antimicrobial
product. Products most frequently prescribed were Fuci-
derm gel (active ingredient fusidic acid; Dechra Veterinary
Products Limited; 105 dogs, 47.7% of 220 dogs), Hibiscrub
(chlorhexidine; Molnlycke Health Care; 77 dogs, 35.0% of
220 dogs) and Malaseb shampoo (miconazole and chlor-
hexidine; Dechra Veterinary Products Limited; 56 dogs,
25.5% of 220 dogs) (Figure 3).
Of the subset of 100 study dogs randomly selected for
detailed case review ten were excluded from further de-
scription due to confirmed (or very likely) violation of
study inclusion criteria: chronological review of all avail-
able free-text clinical history undermined the certainty
of pyoderma diagnosis in eight dogs, and indicated that
the episode identified was not newly diagnosed in 2010
in two more. Thus all available EPR information (includ-
ing free-text) was reviewed in further detail for 90 study
dogs, from 29 individual clinics. Pyoderma lesion depth
was classifiable in 50 of the retained cases, with superfi-
cial lesions the most frequent lesion depth category, re-
ported in 37/50 (74.0%) of these dogs (Table 1). Eighty
two (91%) of the 90 cases reviewed in detail had been pre-
scribed at least one systemic antimicrobial in association
with the pyoderma episode of interest. In all cases antimi-
crobials were dispensed at the practice, with no evidence
of clients being provided with a written prescription to
Figure 1 Antimicrobial formulation type/s initially prescribed by veterinarians treating UK canine pyoderma cases. Frequency and
proportions of all 683 identified canine pyoderma cases prescribed either systemic, topical or both types of antimicrobial agent within 24 hours
of their earliest recorded pyoderma diagnosis in 2010.
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(2.4%) there was evidence that bacterial culture and anti-
microbial sensitivity testing were performed during the
pyoderma episode studied; in both cases results were
available before the prescribed course of antimicrobial
treatment commenced. Test results (indicating no bacter-
ial growth from pyoderma lesion swabs) were available in
the records of one dog (prescribed cefalexin), and were ab-
sent from the records of the other (prescribed cefovecin).Figure 2 Systemic antimicrobial agents initially prescribed or adminis
Prescribing frequency of 12 individual, systemic antimicrobial agents amon
pyoderma diagnosis in 2010 (showing the percentage of these 628 dogs p
were prescribed more than one agent at this time; TMPS, trimethoprim sulComplete information on prescribed daily dose for ad-
ministration was recorded in 80 (97.6%) of the 82 cases
prescribed at least one systemic antimicrobial agent. Me-
dian theoretical total duration of treatment with the ini-
tially prescribed systemic antimicrobial agent was 14 days
(range 1–30 days) and 40.3% (31/77) of the dogs with
available course duration information were prescribed
treatment for a period of less than 14 days (Figure 4). Pre-
scribed daily doses were considered equivalent to thetered by veterinary surgeons treating UK canine pyoderma cases.
g 628 canine pyoderma cases within 24 hours of earliest recorded
rescribed each agent; percentages do not add to 100% as some dogs
phonamide).
Figure 3 Prescribing frequencies of individual topical antimicrobial products among study dogs. Prescribing frequency of individual
topical antimicrobial products among the 220 study dogs prescribed at least one topical antimicrobial within 24 hours of earliest pyoderma
diagnosis in 2010. The percentage of all 683 study dogs prescribed each combination are shown above the relevant bar. Commercial details
(manufacturer and location) for products shown are provided in Additional file 1.
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ficient information available for daily dose calculations),
while the remaining 11 (26%) were prescribed doses below
the recommended level. In 39 cases it was not possible to
determine the MRDD; this was primarily due to absent
weight data, but in 3 dogs prescription of multiple sys-
temic antimicrobial agents concurrently prevented assess-
ment of a single primary agent.
Eight (9%) of the 90 dogs in the subset with pyoderma
were prescribed topical antimicrobial agents only. Available
instructions for administration of topical antimicrobial
agents in these dogs did not indicate (or allow calculation
of) the intended duration of prescribed antimicrobial ther-
apy, or a theoretical date for treatment completion. Sham-
poos or liquid washes were prescribed concurrently with
antimicrobial treatment in 34/90 (37.8%) dogs; Malaseb
(active ingredients miconazole and chlorhexidine) was
prescribed for 18 dogs and either Hibiscrub, Hibitaine
(active ingredient chlorhexidine) or generic chlorhexidine
were prescribed for 16 others.Table 1 Summary of available data on depth of
pyoderma lesions in the 90 episodes reviewed in detail
Stated depth of
pyoderma lesions
Number
of dogs
% of 90 dogs
reviewed in detail
Surface 2 2.2
Superficial 37 41.1
Deep 6 6.7
Mixed (deep + other) 5 5.6
Unclear/ambiguous/absent
clinical description
40 44.4
Total 90 100Discussion
This study explores the prevalence and treatment of ca-
nine pyoderma in a population of UK dogs presented to
primary care veterinary clinics during a single year, based
on EPR data recorded by vets during case management.
Existing studies describing the frequency of bacterial skin
infections in dogs presented for veterinary care are sparse,
have used a variety of case definitions for pyoderma, and
were based on canine populations from different countries
[10-13]. Similarly, while studies reporting prescribing pat-
terns of clinicians treating canine pyoderma in primary
practice are available, they are often relatively small in
scale, not based on UK data, or describe self-reported the-
oretical prescribing behaviour rather than objectively
reporting therapeutic agents dispensed in canine pyo-
derma cases diagnosed in practice [19-22].
Using available electronic data from participating pri-
mary practices it was estimated that approximately 1.1-
1.3% of all dogs presented during 2010 were diagnosed
with pyoderma at least once during that year. However,
the strict case definition applied in this study, as well as
the transient, often recurrent nature of the condition sug-
gest that the level of pyoderma in this population annually
or at any given point in time is likely to be higher than
these estimates. It is particularly relevant to note that the
requirement for use of the specific term ‘pyoderma’ as part
of the criteria for inclusion of a dog as a study case may
have been a particularly important factor in underestima-
tion of true pyoderma frequencies. Based on the data
reviewed, a wide range of terms appear to be used by UK
veterinary practitioners to describe canine dermatological
infections, and diagnostic terms such as “bacterial derma-
titis”, “bacterial folliculitis” or variants of “staphylococcal
Figure 4 Total estimated duration of treatment with the initially prescribed systemic antimicrobial agent in study cases. Total duration
of treatment with the initially prescribed systemic antimicrobial agent (assuming medication dispensed was administered as directed) in 77 of the
82 study cases reviewed in detail, prescribed at least one systemic antimicrobial in association with their earliest pyoderma diagnosis in 2010 and
with sufficient data available to calculate theoretical duration of prescribed treatment.
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ent with clinical pyoderma in many cases. However, it
was not possible to confirm this assumption with suffi-
cient consistency and confidence using the available
data, hence the decision to implement a strict case def-
inition and include only those dogs where recorded
diagnosis included the specific term “pyoderma”. While
it may have been interesting to search EPR data for each
of the potential individual synonyms or equivalent
terms for pyoderma (in parallel with identifying cases
based on use of the specified clinical term) this was not
attempted in the current study due to time constraints.
An additional cause of potential prevalence underesti-
mation relates to the frequent lack of recording of a
diagnosis within clinical fileds: a diagnosis of any kind
was not always stated in dogs presented with skin le-
sions suspicious of pyoderma, even if antimicrobials
were dispensed in association with clinical examination
of the skin. Existing prevalence estimates based on dogs
presented for primary practice care in the UK and USA
are approximately three times higher [10,11], however
validity of comparisons with the estimate from this
study is limited as these surveys were based on different
methodologies for calculation of disease frequency mea-
sures. It is possible that the true prevalence of pyoderma
in the UK pet dog population does lie somewhere be-
tween the estimate in the current study and those previ-
ously reported. However, it is important to note that 8
of the 10 ‘cases’ excluded from the current study after
detailed clinical data review were discarded due to vio-
lation of inclusion criteria. This suggests that the initial
search strategy used to identify pyoderma cases in this
study was not sufficiently accurate to reliably identifycases; this and other potential study limitations are dis-
cussed in more detail later in this report. Antimicrobial
treatment was dispensed or administered at the time of
diagnosis in most pyoderma cases identified. Studies report-
ing antimicrobial prescribing patterns specific to canine
pyoderma are not available for direct comparison, however
this finding is consistent with results of existing surveys
from the UK and New Zealand reporting antimicrobial pre-
scribing in companion animal dermatology cases [10,20]
and surveys of theoretical prescribing behaviour for canine
pyoderma from the UK and Australia [22,23]. These find-
ings are in accordance with current recommendations for
successful treatment of the condition, which agree that
antimicrobial treatment is generally indicated to achieve
clinical resolution of lesions [8,17,18].
Recent, evidence-based guidelines for prudent, effective
management of canine pyoderma emphasize the import-
ance of selecting appropriate antimicrobial therapy (i.e. an
effective agent administered at an adequate dose rate, dos-
ing frequency and course duration) alongside accurate diag-
nosis of lesion depth and management of any underlying
diseases [8,16]. Choice of antimicrobial delivery in the
current study appears to be in line with advice advocating
systemic antimicrobial treatment for most superficial and
all deep pyoderma lesions in dogs, with concurrent topical
antimicrobials or anti-septics useful as adjunctive therapy
[9,16,17,24-26]. While systemic antimicrobial therapy alone
was most common, around a third of cases were prescribed
topical and systemic antimicrobials concurrently. A survey
of theoretical prescribing behaviour among Australian clini-
cians also found that most would prescribe systemic anti-
microbials and an antibacterial shampoo for therapy of
deep pyoderma in dogs [23].
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agents in the present study were amoxicillin-clavulanic
acid, cefalexin (broad-spectrum beta lactams) and clinda-
mycin, all of which are considered appropriate first-line
choices for treatment of straightforward superficial and
surface pyoderma in dogs [16,27]. This finding is consist-
ent with reports from various countries, including the UK,
describing antimicrobial prescribing in companion ani-
mals generally, for dermatological complaints and specific-
ally for treatment of canine pyoderma [10,19-21,28-33].
Bacterial culture and antimicrobial sensitivity testing
was recorded as part of management in only 2% of all
study cases reviewed in detail. Low levels of C&S testing
have also been reported in other studies describing gen-
eral antimicrobial prescribing in companion animals,
and specifically for treatment of canine skin infections
[19,20,29]. In the present study enrofloxacin and cefove-
cin were each prescribed in approximately 5% of cases.
Empirical and first line use of fluoroquinolones or the
3rd generation cephalosporin cefovecin remains contro-
versial for treatment of canine pyoderma, though it can
be useful when difficulties with oral administration of
treatment are experienced or foreseen [16,33,34]. Thus,
the findings of the present study could reflect frequent
empirical selection of these agents for canine pyoderma
in primary practice. It is, however, important to remem-
ber that antimicrobial choice may be dictated by factors
relating to practicality of administration, compliance or
previous adverse drug reactions and assessment of infor-
mation justifying reasons for drug choice was beyond
the scope of this study.
Delivery of a sufficiently high dose of the chosen agent,
at appropriate intervals, is recommended to avoid rapid re-
appearance of lesions while minimizing exposure of bacter-
ial populations to ineffective levels of antimicrobial drugs
[16,17]. Traditionally veterinary surgeons have been ad-
vised to prescribe antimicrobials for 7–14 days beyond
clinical resolution, as confirmed by physical or cytological
examination, though this recommendation does not appear
to be evidence-based. Consistently sub-therapeutic dosing
can lead to poor clinical response, necessitating further
antimicrobial courses and encouraging selection of anti-
microbial resistant bacterial populations [35]. In this study,
around 25% of systemically-treated study dogs reviewed in
detail were prescribed doses below those recommended to
achieve therapeutic levels (minimum MRDD). In addition,
the median treatment duration often appears relatively
short, with antimicrobials prescribed for less than 14 days
in around 40% of cases, even taking into account the likely
predominance of superficial over deep pyoderma cases in
the study population. Other studies report similarly short,
mean treatment periods for canine pyoderma cases in
Finland [21] and New Zealand [20]. Limitations related to
the primary practice setting could curtail treatmentduration regardless of the preferred clinical approach of
the managing practitioner. Economic restrictions, client
preferences and failure to attend for re-examinations
could result in shorter treatment courses than would be
prescribed based on clinical judgement alone. In addition,
the study design did not allow evaluation of client compli-
ance with oral dosing instructions; inconsistent or
under-dosing is reportedly not uncommon in compan-
ion animal practice [36,37]. Therefore, it is possible that
the prescribing-focussed findings reported here over-
estimate the amount and duration of oral antimicrobial
treatment actually received by study dogs prescribed
systemic antimicrobials at or above the MRDD [16].
The study approach was subject to certain inherent
limitations related to the nature of the data used and ca-
nine pyoderma as a clinical condition. The retrospective
data analyzed were not collected primarily for research
purposes, thus researchers had no influence on the con-
tent, level of pyoderma-related detail or note-taking style
of clinical entries and were reliant on the clinical opin-
ion of the examining vet with respect to pyoderma diag-
nosis and progress assessment. The study case definition
for pyoderma required diagnosis to be based on clinical
examination by a veterinarian and recorded using speci-
fied clinical terminology. However, standardised coding of
diagnoses was not consistently applied and the frequency
of typing errors, abbreviation and synonym use as well as
misspelling of clinical terms made case-searching using
the keyword ‘pyoderma’ alone ineffective. The broader
search strategy employed improved the sensitivity of the
search strategy by capturing as many pyoderma cases as
possible, while maintaining strict inclusion criteria to
achieve a reasonable level of diagnostic certainty and spe-
cificity. This method was more time-consuming and still
provided scope for misclassification, i.e. ‘false negatives’
(no explicit statement of pyoderma diagnosis, or diagnosis
expressed in terms inconsistent with the case definition)
and ‘false positives’. In addition, it appeared that few
cases underwent confirmatory diagnostic testing beyond
physical examination. Nonetheless, detailed review of a
sample of cases did enable quantification of the likely
level of uncertainty and misclassification within the
dataset and the majority of identified cases probably in-
volved genuine pyoderma. While it is difficult to quan-
tify the true extent of pyoderma misdiagnosis in this
study, the condition does generally lend itself readily to
diagnosis by simple clinical examination [38], suggest-
ing that the reported prevalence of pyoderma in UK
dogs on an annual basis is likely to be of an order simi-
lar to (or greater than) that reported in this study.
Further limitations included missing or erroneously re-
corded data of interest; certain data fields were frequently
unpopulated, or contained information which proved in-
correct based upon full review of clinical notes. Data on
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pite review of all available free-text data entries, limiting
comprehensive description of study animals and evalu-
ation of certain variables of interest in the study. A par-
ticular example was the frequent absence of recorded data
on follow-up for study cases: re-examinations to confirm
clinical resolution appeared to occur relatively infre-
quently, even when advised by the prescribing clinician.
Thus it was not possible to describe (or explore factors po-
tentially affecting) clinical response to antimicrobial treat-
ment or recurrence of pyoderma lesions after completion
of prescribed therapy. In this study it is likely that the con-
straints of the clinical setting had a major influence on the
data available for clinicians to report as well as the depth
of information recorded: in private, primary-care practice
non-clinical factors (such as client financial constraints or
convenience) often drive decisions on diagnostic approach,
case management, as well as the occurrence and timing of
any follow-up clinical evaluations. In addition, the time
available to busy veterinary surgeons for clinical recording
can be limited. However, the data accurately reflect pre-
scribing behaviour of primary practice veterinarians with
respect to a larger number of UK canine pyoderma cases
than previously described, underlining the potential of EPR
data for use in large scale epidemiological studies and
practice-based surveillance.
Conclusions
Approximately 1.1-1.3% of nearly 55,000 dogs attending
UK primary practices during 2010 were diagnosed with
pyoderma during that year, however this is likely to be a
conservative estimate of the true prevalence of the con-
dition in this population at any given time. Study find-
ings suggested that there is scope for improvement with
respect to prudent antimicrobial use in canine pyoderma
treatment in UK primary-care practice, in terms of em-
pirical selection of certain critically important agents,
prescribing of adequate dose rates and particularly suffi-
cient treatment duration. This report highlights the
value of practice-based electronic health records for
prevalence estimation and description of clinical man-
agement of conditions commonly seen in vet-visiting ca-
nine populations presented for primary health care.
Methods
Clinical and animal data from consultations recorded dur-
ing a single year (2010) were exported for analysis from a
database containing all de-identified patient records from
dogs attending UK primary-care veterinary clinics partici-
pating in the VetCompass Animal Surveillance project
[39]. These practices form a convenience sample based on
established use of an appropriately configured practice
management system (PMS) for clinical record keeping
and willingness to contribute clinical data for researchpurposes. Data from individual practices were extracted
centrally via a bespoke clinical reporting query estab-
lished with the participating practices and groups. Data
were uploaded to a File Transfer Protocol (FTP) site,
then imported into and stored in the VetCompass struc-
tured query language (SQL) database held securely on
an RVC server.
Ethical approval was obtained from the Royal Veterin-
ary College (RVC) Ethics and Welfare Committee for
the extraction, transfer, secure storage and use of speci-
fied data from first opinion patient health records for
the purposes of this projecta. Procedures for data extrac-
tion, storage and reporting of analyses were compliant
with data protection legislation (P Dron, RVC Data pro-
tection officer; Personal communication). Approval for
project aims and data collection approach was obtained
from the Royal College of Veterinary Surgeons (RCVS).
Consent for the use of clinical data was obtained from
senior practice managers on behalf of all participating
clinics, on the basis that that no animal or client would
be identifiable in published findings.
Extracted data fields included patient characteristics
(breed, gender, neutering status, date of birth), consultation-
related data (date of examination or clinical data entry, free-
text clinical notes, any diagnostic codes assigned (VeNom
codes [40]) and treatment details (product name and num-
ber of items dispensed, dosing instructions from labels gen-
erated for dispensed medication). Fields directly identifying
participating animals, owners or financial information were
not extracted.
Data cleaning and processing was carried out in SQL
using a Microsoft Access interface. Participating centres
(identifiable in the extracted data to the level of clinic ID
number) were assigned unique numerical codes allowing
differentiation between clinics in the analysis without
compromising participant anonymity. Recorded breed
data were standardised according to a pre-existing scheme
of canine breed terminology (VeNom codes [40]).
The study case definition for pyoderma required diagno-
sis to be based on clinical examination by a veterinarian
and recorded using specified clinical terminology. Poten-
tial study cases were initially identified using the Microsoft
Access interface to search for clinical entries where free-
text clinical data or diagnostic code fieldsb contained the
word-root ‘pyo’, with date restrictions applied limiting
search results to entries recorded in 2010. All clinical in-
formation recorded in the entries highlighted was then
reviewed to confirm that the identified ‘pyo’ word-root did
appear to indicate an appropriately recordedc, positive
diagnosis of pyoderma made by a clinician and based on
physical examination. It was also confirmed that the diag-
nosis documented a pyoderma episode newly diagnosed in
the year 2010 (i.e. not continuation of an ongoing episode
diagnosed the previous year). Dogs with at least one
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for inclusion. In dogs with more than one recorded pyo-
derma diagnosis during 2010 the earliest recorded diagnosis
was selected for description and defined as the pyoderma
episode of interest. The start of this episode was defined as
the date that diagnosis was first recorded in the PMS clin-
ical records.
Microsoft Access queries were designed to extract fields
containing clinical data recorded on the date of diagnosis of
the pyoderma episode of interest, product details and
amounts (volume or unit number) of medications dispensed
or administered on this date, and general signalment data
(breed, sex, neutering status) for all selected dogs.
In all study dogs, confirmation of diagnosis with a pyo-
derma episode in 2010 was initially based only on the
earliest free-text clinical entry identified by the search
strategy. Similarly description of basic signalment infor-
mation across all study dogs related only to information
extracted from the relevant specific data fields and was
not based on review of all available clinical text. Age at
diagnosis of the episode of interest was calculated using
recorded date of birth and diagnosis date. Where pos-
sible, weight data recorded on (or as close as possible to)
the date of diagnosis were extracted. Treatment informa-
tion was extracted from records of item sales occurring
within 24 hours of recorded diagnosis of the pyoderma
episode of interest. Treatment-related factors included
the name (generic and product) and route of administra-
tion of the first systemic antimicrobial agent prescribed
to treat the identified pyoderma episode. Prescribing of
topical antimicrobials, systemic steroids, anti-parasitic
and anti-fungal agents at this time was also recorded.
To allow estimation of pyoderma prevalence the Vet-
Compass database was queried to determine the total
number of unique canine patients presented to partici-
pating practices for any reason during 2010. This was
used as denominator data in calculations estimating the
prevalence of diagnosis with at least one pyoderma epi-
sode in UK dogs presented to first opinion practice dur-
ing the year 2010. Prevalence and the 95% CIs were
calculated by standard methods [41].
Additional clinical data from a random subset of
study dogs
Random number generation (using Microsoft Excel (12.0)
[Microsoft Corporation, Redmond, WA, USA]) was used
to select a subset sample of at least 10% of the dogs identi-
fied as pyoderma cases by the initial search criteria. These
selected cases were reviewed in depth, including evalu-
ation of disease and treatment details, follow-up of clinical
progression and validation of the initial case-finding ap-
proach. Queries were designed to extract all clinical en-
tries associated with these dogs from the original database
on dates up to and including the 31st December 2011.Chronological review of all available free-text clinical his-
tory was undertaken for each dog to assess the validity of
selection as a pyoderma case and to describe pyoderma le-
sion depth, underlying cause and treatment-related infor-
mation in greater detail.
Pyoderma depth was categorised as either ‘surface’, ‘super-
ficial’, ‘deep’, or ‘mixed’ based on lesion description state-
ments recorded by the examining clinician [8]. Cases were
classified into one of three groups with respect to diagnosis
of a primary cause: if at least one primary disease diagnosis
was explicitly stated in clinical notes, based on reported
diagnostic tests, prior diagnostic history or (in the absence
of these data), strongly expressed suspicion of the man-
aging clinician after clinical examination) classification
was ‘confirmed diagnosis of primary condition/s’, and spe-
cific conditions were recorded. Cases with no stated pri-
mary disease diagnosis and no evidence for performance
of relevant diagnostic testing were classed as having either
‘suggested primary cause/s only’ or having ‘no stated or
suggested primary cause’.
Additional treatment-related data extracted for this sub-
set included the daily dosing instructions and total number
of units (tablets/capsules/volume of injectable formulation)
of any initially prescribed systemic antimicrobial agent dis-
pensed across all consecutive prescribing events during the
studied pyoderma episode. Based on calculations using pa-
tient weight (as recorded on the date of diagnosis) and drug
manufacturers’ recommended daily dose (MRDD) rates for
treatment of canine pyoderma [42], dogs were classified as
having been prescribed at least the minimum MRDD or a
dose below this level. Where total duration of prescribed
treatment with the systemic antimicrobial agent of interest
was not explicitly stated, a theoretical total course length
based on units dispensed and dosing instructions was cal-
culated whenever possible.
Non-antimicrobial treatments prescribed or adminis-
tered to study dogs concurrently with the systemic anti-
microbial agent of interest were also recorded. Where
appropriate, prescribed products were classified (based on
active ingredients, formulation, instructions for use when
prescribed and clinical opinion of a board certified veterin-
ary dermatologist) into one or more of the following cat-
egories, highlighted due to their potential relevance in
cases of skin infection: Systemic steroids, antifungal
agents and anti-ectoparasitic agentsd. Concurrent pre-
scription of shampoos or liquid washes (including non-
medicated products) was noted to reflect the intention
for regular physical bathing of the skin and coat.
Statistical analysis
Data were cleaned in Microsoft Excel (version 12.0;
Microsoft Corporation, Redmond, WA, USA). Statis-
tical analysis was carried out using Stata (version 11.0;
Statacorp, Texas, USA). Variables were categorised
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for all study dogs with respect to signalment factors and
antimicrobial product/s prescribed within 24 hours of
recorded diagnosis of the pyoderma episode of interest.
Additional descriptive statistics were calculated for the
randomly selected subset of pyoderma cases described in
greater detail, including lesion depth, duration of sys-
temic antimicrobial treatment prescribed and adequacy
of prescribed daily dose compared with MRDD. The ex-
tent of missing or insufficiently specific data was sum-
marized. Mean and standard deviation or median and
range were used for the description of quantitative data
as appropriate while qualitative data were described
using frequencies with percentage of stated totals.
Endnotes
aRVC Ethics Committee, March 2009.
bThe recording format of the PMS used by participating
practices included opportunities for standardised termin-
ology based on the VeNom codes.
cStudy protocol included a list of terminology accepted
as compatible with pyoderma for study purposes, based
on clinical codes defined by the VeNom Coding group.
Some notable exceptions were also specified, e.g. pyo-
traumatic dermatitis.
dFull category listings are provided in Additional file 1.
Additional file
Additional file 1: Classification of therapeutic products prescribed
concurrently with systemic antimicrobial treatment. Description of
data: Classification of prescribed products into groups of particular
potential relevance in cases of canine skin infection (based on active
ingredients, formulation, instructions for use when prescribed and clinical
opinion of a specialist, board certified veterinary dermatologist).
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